EP1578792A2 - Nouvelle proteine associee aux centrosomes et ses applications - Google Patents
Nouvelle proteine associee aux centrosomes et ses applicationsInfo
- Publication number
- EP1578792A2 EP1578792A2 EP03813937A EP03813937A EP1578792A2 EP 1578792 A2 EP1578792 A2 EP 1578792A2 EP 03813937 A EP03813937 A EP 03813937A EP 03813937 A EP03813937 A EP 03813937A EP 1578792 A2 EP1578792 A2 EP 1578792A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- protein
- seq
- polynucleotide
- asap
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102100028845 Biogenesis of lysosome-related organelles complex 1 subunit 2 Human genes 0.000 title abstract 2
- 101000935458 Homo sapiens Biogenesis of lysosome-related organelles complex 1 subunit 2 Proteins 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 173
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 145
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 75
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 75
- 239000002157 polynucleotide Substances 0.000 claims abstract description 75
- 230000002018 overexpression Effects 0.000 claims abstract description 11
- 230000001594 aberrant effect Effects 0.000 claims abstract description 8
- 101001016777 Homo sapiens Microtubule-associated protein 9 Proteins 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 74
- 102100032485 Microtubule-associated protein 9 Human genes 0.000 claims description 57
- 239000012634 fragment Substances 0.000 claims description 37
- 239000013598 vector Substances 0.000 claims description 34
- 102000053702 human MAP9 Human genes 0.000 claims description 33
- 239000000523 sample Substances 0.000 claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 239000012472 biological sample Substances 0.000 claims description 25
- 239000000126 substance Substances 0.000 claims description 23
- 230000000394 mitotic effect Effects 0.000 claims description 22
- 108020004414 DNA Proteins 0.000 claims description 21
- 230000003321 amplification Effects 0.000 claims description 20
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 18
- 238000009448 modified atmosphere packaging Methods 0.000 claims description 17
- 230000014509 gene expression Effects 0.000 claims description 16
- 238000013518 transcription Methods 0.000 claims description 14
- 230000035897 transcription Effects 0.000 claims description 14
- 101150107708 Asap gene Proteins 0.000 claims description 13
- 238000009396 hybridization Methods 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 12
- 230000009261 transgenic effect Effects 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 241001529936 Murinae Species 0.000 claims description 10
- 230000004075 alteration Effects 0.000 claims description 10
- 230000003834 intracellular effect Effects 0.000 claims description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 9
- 238000010367 cloning Methods 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 9
- 230000008520 organization Effects 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 230000000692 anti-sense effect Effects 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 5
- 238000012163 sequencing technique Methods 0.000 claims description 5
- 108020004635 Complementary DNA Proteins 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 238000011156 evaluation Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 235000019837 monoammonium phosphate Nutrition 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 239000013599 cloning vector Substances 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 230000002927 anti-mitotic effect Effects 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 230000008105 immune reaction Effects 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 238000010839 reverse transcription Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 230000007046 spindle assembly involved in mitosis Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 69
- 102000029749 Microtubule Human genes 0.000 description 21
- 108091022875 Microtubule Proteins 0.000 description 21
- 239000002299 complementary DNA Substances 0.000 description 21
- 210000004688 microtubule Anatomy 0.000 description 21
- 238000003752 polymerase chain reaction Methods 0.000 description 19
- 210000004899 c-terminal region Anatomy 0.000 description 15
- 102000004243 Tubulin Human genes 0.000 description 14
- 108090000704 Tubulin Proteins 0.000 description 14
- 210000003793 centrosome Anatomy 0.000 description 14
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 13
- 230000009368 gene silencing by RNA Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 108091030071 RNAI Proteins 0.000 description 11
- 239000005090 green fluorescent protein Substances 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 10
- 210000001550 testis Anatomy 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 9
- 238000010166 immunofluorescence Methods 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000032823 cell division Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 230000011278 mitosis Effects 0.000 description 8
- 230000002285 radioactive effect Effects 0.000 description 8
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 7
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102000001421 BRCT domains Human genes 0.000 description 6
- 108050009608 BRCT domains Proteins 0.000 description 6
- 108700024394 Exon Proteins 0.000 description 6
- 102000001253 Protein Kinase Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000030570 cellular localization Effects 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000004807 localization Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 108060006633 protein kinase Proteins 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 102000010111 Ezrin/radixin/moesin Human genes 0.000 description 5
- 108050001788 Ezrin/radixin/moesin Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000021953 cytokinesis Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000000636 Northern blotting Methods 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000005441 aurora Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000019305 Microtubule associated protein 1A Human genes 0.000 description 3
- 108050006673 Microtubule associated protein 1A Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000016507 interphase Effects 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000132092 Aster Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108091060290 Chromatid Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 241000490229 Eucephalus Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 2
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 102000028861 calmodulin binding Human genes 0.000 description 2
- 108091000084 calmodulin binding Proteins 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000002230 centromere Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000004756 chromatid Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000000375 direct analysis in real time Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000012063 dual-affinity re-targeting Methods 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000000688 human artificial chromosome Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000002415 kinetochore Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000031877 prophase Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000016853 telophase Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101001057325 Arabidopsis thaliana Methionine aminopeptidase 1A Proteins 0.000 description 1
- 101100519160 Arabidopsis thaliana PCR4 gene Proteins 0.000 description 1
- 102000004000 Aurora Kinase A Human genes 0.000 description 1
- 108090000461 Aurora Kinase A Proteins 0.000 description 1
- 102000004228 Aurora kinase B Human genes 0.000 description 1
- 108090000749 Aurora kinase B Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 244000258136 Costus speciosus Species 0.000 description 1
- 235000000385 Costus speciosus Nutrition 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100458289 Drosophila melanogaster msps gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000010638 Kinesin Human genes 0.000 description 1
- 108010063296 Kinesin Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 101710093531 Microtubule-associated protein 9 Proteins 0.000 description 1
- 101150008132 NDE1 gene Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000004718 centriole Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000011855 chromosome organization Effects 0.000 description 1
- 230000024321 chromosome segregation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 239000000891 luminescent agent Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000005080 phosphorescent agent Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the protein according to the invention consists of the chain of 13 peptides corresponding to the translation products of 13 of the 14 exons that contains the corresponding gene, the first exon not being translated (see below).
- - Peptide 7 it comprises 24 amino acids corresponding to positions 351 to 374 (SEQ ID NO: 8); - Peptide 8: it comprises 54 amino acids corresponding to positions 375 to 428 (SEQ ID NO: 9);
- sequences SEQ ID NO: 47 to 53 corresponding to mutants of the hASAP protein deleted from the N-terminal part containing the BRCT domain (NdeM: residues 304 -647 (SEQ ID NO: 48); Ndel2: residues 411-647 (SEQ ID NO: 49); Ndel3: residues 478-647 (SEQ ID NO: 50)) or of the C-terminal part containing the MAP domain (CdeM: residues 1 to 477 (SEQ ID NO: 51); Cdel2: residues 1 to 418 (SEQ ID NO: 52); Cdel3: residues 1 to 303 (SEQ ID NO: 53); residues 1 to 421 (SEQ ID NO: 47)).
- said peptide is useful for the production of antibodies specifically recognizing a protein as defined above, preferably recognizing the ASAP protein of sequence SEQ ID NO: 1 or SEQ ID NO: 46 .
- the subject of the invention is also a kit of reagents for the implementation of the methods described above comprising: a) at least one probe or a pair of primers according to the invention; b) the reagents necessary for carrying out a conventional hybridization reaction between said probe or said primers and the nucleic acid of the biological sample; c) the reagents necessary for carrying out an amplification reaction; d) the reagents necessary for the detection and / or the assay of the hybrid formed between said probe and the nucleic acid of the biological sample or of the amplified nucleic acids formed.
- Such substances can be biological macromolecules such as for example a nucleic acid, a lipid, a sugar, a protein, a peptide, a hybrid protein-lipid compound, protein-sugar, peptide-iipid or peptide-sugar, a protein or a peptide to which chemical ramifications have been added or chemical molecules.
- the invention also relates to the polynucleotide, the protein, the antibodies, the vectors or the cells transformed according to the invention, used as medicaments.
- Hoechst 33286 (4A: 63x objective; 4B, 4C, 4D: I00X objective).
- YFP-FIS1 F (5'-AATGTCTGATGAAG I I I I IAGCACC-3 ') (SEQ ID NO: 41)
- the vectors obtained are transfected according to the calcium phosphate technique or more routinely using the jetPE1 process (GDSP10101, Qbiogene) according to the manufacturer's recommendations, in the following cell lines:
- FIG. 5 illustrates the co-location of the human ASAP protein with alpha-tubulin; similarly the murine ASAP protein co-locates with alpha-tubulin.
- RNAi interfering RNA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0216648A FR2849039B1 (fr) | 2002-12-24 | 2002-12-24 | Nouvelle proteine associee aux centrosomes et ses applications |
FR0216648 | 2002-12-24 | ||
PCT/FR2003/003895 WO2004058815A2 (fr) | 2002-12-24 | 2003-12-24 | Proteine associee aux centrosomes et ses applications |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1578792A2 true EP1578792A2 (fr) | 2005-09-28 |
Family
ID=32406499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03813937A Withdrawn EP1578792A2 (fr) | 2002-12-24 | 2003-12-24 | Nouvelle proteine associee aux centrosomes et ses applications |
Country Status (7)
Country | Link |
---|---|
US (2) | US7402394B2 (ja) |
EP (1) | EP1578792A2 (ja) |
JP (1) | JP4660200B2 (ja) |
AU (1) | AU2003303464A1 (ja) |
CA (1) | CA2511436A1 (ja) |
FR (1) | FR2849039B1 (ja) |
WO (1) | WO2004058815A2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120117931A (ko) | 2010-02-12 | 2012-10-24 | 온코메드 파마슈티칼스, 인크. | 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003518364A (ja) * | 1999-05-28 | 2003-06-10 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 乳癌、胃癌および前立腺癌関連抗原ならびにそれらの使用 |
US6783969B1 (en) * | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
-
2002
- 2002-12-24 FR FR0216648A patent/FR2849039B1/fr not_active Expired - Fee Related
-
2003
- 2003-12-24 CA CA002511436A patent/CA2511436A1/fr not_active Abandoned
- 2003-12-24 EP EP03813937A patent/EP1578792A2/fr not_active Withdrawn
- 2003-12-24 US US10/540,493 patent/US7402394B2/en not_active Expired - Fee Related
- 2003-12-24 JP JP2004563311A patent/JP4660200B2/ja not_active Expired - Fee Related
- 2003-12-24 WO PCT/FR2003/003895 patent/WO2004058815A2/fr active Application Filing
- 2003-12-24 AU AU2003303464A patent/AU2003303464A1/en not_active Abandoned
-
2008
- 2008-07-07 US US12/216,510 patent/US20090275024A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2004058815A2 * |
Also Published As
Publication number | Publication date |
---|---|
JP4660200B2 (ja) | 2011-03-30 |
US20060216710A1 (en) | 2006-09-28 |
US20090275024A1 (en) | 2009-11-05 |
WO2004058815A3 (fr) | 2005-03-17 |
JP2006526387A (ja) | 2006-11-24 |
WO2004058815B1 (fr) | 2005-05-06 |
US7402394B2 (en) | 2008-07-22 |
FR2849039B1 (fr) | 2010-10-01 |
FR2849039A1 (fr) | 2004-06-25 |
AU2003303464A8 (en) | 2004-07-22 |
AU2003303464A1 (en) | 2004-07-22 |
CA2511436A1 (fr) | 2004-07-15 |
WO2004058815A2 (fr) | 2004-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0868512B9 (fr) | Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer | |
WO2001032704A1 (fr) | Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline | |
Saur et al. | Site-specific gene expression of nNOS variants in distinct functional regions of rat gastrointestinal tract | |
Borsu et al. | The AROM gene, spliced mRNAs encoding new DNA/RNA-binding proteins are transcribed from the opposite strand of the melanin-concentrating hormone gene in mammals | |
EP0980427B1 (fr) | Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques | |
Caldwell et al. | The novel kinase peptidylglycine α-amidating monooxygenase cytosolic interactor protein 2 interacts with the cytosolic routing determinants of the peptide processing enzyme peptidylglycine α-amidating monooxygenase | |
Fritzius et al. | WD‐repeat‐propeller‐FYVE protein, ProF, binds VAMP2 and protein kinase Cζ | |
Johnston et al. | Harp (harmonin‐interacting, ankyrin repeat‐containing protein), a novel protein that interacts with harmonin in epithelial tissues | |
EP1578792A2 (fr) | Nouvelle proteine associee aux centrosomes et ses applications | |
EP1259606B1 (fr) | Compositions utilisables pour reguler l'activite de la parkine | |
WO2001077323A1 (fr) | Gene codant pour l'erbin et utilisations diagnostiques et therapeutiques | |
WO2003040369A2 (fr) | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments | |
US20030054418A1 (en) | Gene and sequence variation associated with cancer | |
EP1257642B1 (fr) | Partenaires du domaine ptb1 de fe65, preparation et utilisations | |
WO2003025176A2 (fr) | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments | |
US8138307B2 (en) | Parkin interacting polypeptides and methods of use | |
WO2001085955A1 (fr) | Polypeptide rh116 et ses fragments et polynucleotides codant lesdits polypeptides et applications thérapeutiques | |
WO2003025177A2 (fr) | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments | |
WO2003087153A1 (fr) | Proteine knox-25 en doigt de zinc de type kruppel de souris et son utilisation | |
WO2001031003A1 (fr) | Clonage, expression et caracterisation d'un gene exprime dans des cellules tumorales et implique dans la regulation de la reponse immune | |
WO2002052004A1 (fr) | Gene implique dans la regulation de l'apoptose | |
WO2003087372A2 (fr) | Facteur de croissance derive d’hepatome et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050701 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20080415 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20120703 |